NCT07910019
Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Baseline natural cytotoxicity of CSPC and CRPC patients' natural killer cells
Timeframe: Through study completion, an average of 1 year
Broad immune landscape
Timeframe: Through study completion, an average of 1 year
Analysis of biopsy samples
Timeframe: Through study completion, an average of 1 year
Effects on NK cells treated with IL-15, camB7-H3 TriKE, scFv PSMA TriKE, or camB7-H3/PSMA TriKE-PACC
Timeframe: Through study completion, an average of 1 year
Ability of the 5 treatments to mitigate tumor burden
Timeframe: Through study completion, an average of 1 year
Arms and interventions
Observational
Patients undergo collection of blood samples and have their medical records reviewed on study. Patients may undergo collection of residual tissue samples, if available, on study.
Other: Non-Interventional Study
Sites
1 site in 1 country
- University of Minnesota/Masonic Cancer CenterMinneapolis, Minnesota, United States